Forensic Analysis · Industrials / Manufacturing / Defense · as of Oct 13, 2026

Nexalin Technology, Inc. (NXL)

A forensic read on Nexalin Technology, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Distress

Financial health

-68.2

Distress distance

Clean

Earnings quality

Forensic signals

-219.4%

ROE

78.8%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Nexalin Technology, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -68.2, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+49.3%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +123% over the last 2 years to FY2025 (+49.3%/yr). The count is growing — 7.4M shares in FY2023, 16.4M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~49.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~55%.

1035% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 1035% of revenue in FY2025 — about $0.19 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 49.3% a year across FY2023–FY2025 and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.

Key fundamentals

Latest Revenue$301,647.00

Revenue Growth YoY+78.8%

Revenue CAGR (2yr)+65.0%

Net Margin-2725.8%

Return on Equity-219.4%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Nexalin Technology, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Oct 13, 2026. Forensic signals flag probability, not certainty.